Table 2.
Cumulative 1-year incidences of acute liver injury (and ancillary outcome) and hazard ratios for each type of NOAC compared to VKA, in patients with no prior liver disease (main study population).
| Type of OAC | N patients | N events | Follow-up in days (mean ± SD) | Crude cumulative 1-year incidence with 95% CI (per 10,000) | Cumulative 1-year incidence with 95% CI after IPTW* (per 10,000) | Crude HR with 95% CI | HR after IPTW with 95% CI |
|---|---|---|---|---|---|---|---|
| Hospitalised acute liver injury | |||||||
| VKA | 220,367 | 117 | 339 ± 70 | 5.6 (4.7–6.7) |
Dabigatran: 5.3 (4.6–6.0) Rivaroxaban: 5.1 (4.4–5.8) Apixaban: 5.3 (4.6–6.1) |
Reference | Reference |
| Dabigatran | 51,737 | 26 | 350 ± 49 | 5.1 (3.5–7.5) | 6.2 (4.0–8.3) | 0.92 (0.60–1.41) | 1.17 (0.79–1.75) |
| Rivaroxaban | 99,408 | 46 | 351 ± 48 | 4.7 (3.6–6.3) | 7.2 (4.5–9.8) | 0.85 (0.60–1.19) | 1.41 (1.05–1.91) |
| Apixaban | 62,503 | 29 | 349 ± 51 | 4.8 (3.3–6.9) | 4.4 (2.4–6.3) | 0.85 (0.57–1.28) | 0.82 (0.53–1.25) |
| Elevation of transaminases (proxy, ancillary outcome) | |||||||
| VKA | 220,367 | 7537 | 333 ± 80 | 358.0 (350.2–366.1) |
Dabigatran: 348.1 (342.5–353.6) Rivaroxaban: 343.2 (336.9–349.5) Apixaban: 349.3 (342.9–355.7) |
Reference | Reference |
| Dabigatran | 51,737 | 1353 | 345 ± 61 | 267.3 (253.6–281.7) | 297.2 (280.5–314.0) | 0.74 (0.70–0.79) | 0.85 (0.81–0.90) |
| Rivaroxaban | 99,408 | 2877 | 345 ± 61 | 295.6 (285.1–306.4) | 334.1 (320.9–347.2) | 0.82 (0.79–0.86) | 0.97 (0.93–1.01) |
| Apixaban | 62,503 | 1958 | 343 ± 64 | 320.7 (307.0–335.0) | 351.7 (334.8–368.7) | 0.89 (0.85–0.94) | 1.01 (0.96–1.06) |
CI confidence interval, HR hazard ratio, IPTW inverse probability of treatment weighting, NOAC non-vitamin K antagonist oral anticoagulant, OAC oral anticoagulant, SD standard deviation, VKA vitamin K antagonist.
*Calculated for each of the three comparisons.